Can-Fite Targets Licensing Deals for Late-Stage Oncology and Liver Disease Drugs at BIO 2026
Event summary
- Can-Fite BioPharma will present its late-stage clinical pipeline at BIO International Convention 2026, held June 22–25 in San Diego.
- The company will conduct partnering meetings focused on licensing and commercialization opportunities for its oncology, liver disease, and inflammatory disease drugs.
- Namodenoson, its lead drug candidate, is in a pivotal Phase III study for advanced hepatocellular carcinoma (HCC) and a Phase IIb study for MASH.
- Piclidenoson, another drug candidate, is in a pivotal Phase III study for psoriasis and preparatory work for a Phase II study in Lowe Syndrome.
- Can-Fite has generated approximately $20 million in upfront and milestone payments from regional licensing agreements.
The big picture
Can-Fite's participation in BIO International Convention 2026 underscores the biotechnology industry's focus on strategic partnerships and licensing deals to accelerate drug development. The company's advanced clinical-stage pipeline positions it to capitalize on the growing demand for innovative therapies in oncology, liver disease, and inflammatory conditions. With a favorable safety profile demonstrated in over 1,600 patients, Can-Fite's A3 adenosine receptor (A3AR) platform technology is a key asset in its pursuit of global value creation.
What we're watching
- Licensing Momentum
- Whether Can-Fite can secure additional licensing deals to bolster its revenue and expand its global reach.
- Clinical Trial Progress
- The pace at which Namodenoson and Piclidenoson advance through their respective Phase III trials and the potential for regulatory approvals.
- Strategic Partnerships
- How Can-Fite's partnering meetings at BIO 2026 will impact its long-term strategic collaborations and commercialization efforts.
Related topics